WAVE Life Sciences Ltd. (NASDAQ:WVE) Stock Has Average Price Target of $20.44 According to Brokerages

WAVE Life Sciences logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analyst sentiment is broadly positive: 20 firms give WAVE Life Sciences a “Moderate Buy” consensus, with 15 buy and two strong-buy ratings. The average 12-month price target is $20.44, though Citigroup recently cut its target to $15.
  • Shares opened at $2.84, near their 12-month low of $2.77 and well below the 12-month high of $21.73.
  • WAVE reported quarterly EPS of -$0.30, beating the -$0.33 consensus, and revenue of $13.16 million versus analysts’ $4.51 million estimate. Institutional investors and hedge funds own 89.73% of the stock.
  • MarketBeat previews top five stocks to own in December.

WAVE Life Sciences Ltd. (NASDAQ:WVE - Get Free Report) has received an average recommendation of "Moderate Buy" from the twenty research firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation, fifteen have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $20.44.

Several analysts have recently weighed in on the stock. Citigroup lowered their target price on shares of WAVE Life Sciences from $19.00 to $15.00 and set a "buy" rating on the stock in a report on Thursday, November 12th. Zacks Research cut shares of WAVE Life Sciences from a "strong-buy" rating to a "hold" rating in a report on Wednesday, August 19th. Ladenburg Thalmann & Co. Inc. assumed coverage on shares of WAVE Life Sciences in a research report on Thursday, October 1st. They issued a "buy" rating and a $10.00 price objective for the company. B. Riley Financial restated a "buy" rating and issued a $18.00 price objective on shares of WAVE Life Sciences in a research report on Monday, November 9th. Finally, HC Wainwright initiated coverage on WAVE Life Sciences in a report on Wednesday, October 28th. They issued a "strong-buy" rating on the stock.

Check Out Our Latest Analysis on WVE

Institutional Trading of WAVE Life Sciences

Hedge funds have recently modified their holdings of the business. Readystate Asset Management LP acquired a new stake in shares of WAVE Life Sciences in the second quarter valued at about $27,465,000. Squarepoint Ops LLC boosted its holdings in WAVE Life Sciences by 68.0% during the second quarter. Squarepoint Ops LLC now owns 2,541,442 shares of the company's stock worth $14,766,000 after buying an additional 1,029,052 shares in the last quarter. Marshall Wace LLP increased its holdings in WAVE Life Sciences by 266.5% in the third quarter. Marshall Wace LLP now owns 3,663,275 shares of the company's stock valued at $13,554,000 after buying an additional 2,663,742 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in WAVE Life Sciences by 5.5% in the third quarter. Goldman Sachs Group Inc. now owns 1,711,417 shares of the company's stock valued at $6,332,000 after buying an additional 89,075 shares in the last quarter. Finally, Renaissance Technologies LLC increased its holdings in WAVE Life Sciences by 152.6% in the first quarter. Renaissance Technologies LLC now owns 597,220 shares of the company's stock valued at $4,330,000 after buying an additional 360,800 shares in the last quarter. 89.73% of the stock is owned by institutional investors and hedge funds.

WAVE Life Sciences Price Performance

WAVE Life Sciences stock opened at $2.84 on Wednesday. WAVE Life Sciences has a 12 month low of $2.77 and a 12 month high of $21.73. The business has a 50 day simple moving average of $3.65 and a 200-day simple moving average of $6.87. The stock has a market capitalization of $560.13 million, a PE ratio of -2.65 and a beta of -1.40.

WAVE Life Sciences (NASDAQ:WVE - Get Free Report) last announced its quarterly earnings data on Tuesday, October 27th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.03. The company had revenue of $13.16 million for the quarter, compared to analysts' expectations of $4.51 million. WAVE Life Sciences had a negative net margin of 296.86% and a negative return on equity of 44.66%. As a group, equities research analysts anticipate that WAVE Life Sciences will post -1.08 EPS for the current year.

About WAVE Life Sciences

(Get Free Report)

WAVE Life Sciences Ltd. is a biotechnology company developing RNA-based medicines for genetically defined diseases. Founded in 2012, the company is headquartered in Cambridge, Massachusetts, and uses its oligonucleotide chemistry and drug-design capabilities to develop treatments intended to alter or regulate gene expression. Its research includes antisense oligonucleotide therapies and RNA-editing approaches. Programs have targeted conditions such as Huntington's disease and alpha-1 antitrypsin deficiency, with the latter exploring RNA editing to address a disease-causing genetic variant.

Recommended Stories

Analyst Recommendations for WAVE Life Sciences (NASDAQ:WVE)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in WAVE Life Sciences Right Now?

Before you consider WAVE Life Sciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and WAVE Life Sciences wasn't on the list.

While WAVE Life Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines